Brokerages Set GSK plc (LON:GSK) PT at GBX 2,034.29

Shares of GSK plc (LON:GSK) have received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 2,034.29.

A number of analysts recently issued reports on GSK shares. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a research note on Monday, June 8th. Citigroup reduced their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Berenberg Bank reissued a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Thursday, March 26th.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds acquired 1,550 shares of GSK stock in a transaction that occurred on Friday, June 19th. The stock was bought at an average price of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Wendy Becker acquired 4,000 shares of GSK stock in a transaction that occurred on Wednesday, April 29th. The stock was acquired at an average cost of GBX 1,963 per share, with a total value of £78,520. Over the last ninety days, insiders purchased 7,630 shares of company stock worth $21,357,859. 0.31% of the stock is currently owned by corporate insiders.

GSK Stock Down 0.6%

Shares of LON GSK opened at GBX 1,972.50 on Monday. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. The firm has a market capitalization of £79.11 billion, a price-to-earnings ratio of 13.88, a PEG ratio of 1.24 and a beta of 0.29. The stock has a 50 day moving average price of GBX 1,939.56 and a 200 day moving average price of GBX 1,969.38. GSK has a 52-week low of GBX 1,288.61 and a 52-week high of GBX 2,282.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The firm had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Sell-side analysts expect that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.